New horizon for radical cure of chronic hepatitis B virus infection

doi:10.4254/wjh.v8.i21.863

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11161)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

920

WORD

303

HTML

5588

Figures (1-1)

206

Tables (1-2)

242

Sum=7259

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

417

Download

620

Sum=1037

Publishing Process of This Article

Item

Count

Browse

1064

Download

1801

Sum=2865

Jul 28, 2016 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Jul 28, 2016; 8(21): 863-873
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.863

Table 2 Tgerapectic agents against hepatitis B virus currently in clinical development

Mode of actions	Target	Stage of development	Ref.
Entry inhibitions	NTCP	Myrcludex in phage 2	[14,123]
cccDNA
Formation inhibitions	DSS	Preclinical	[99]
Transcription inhibitions	ASO	IONIS-HBVRx in phase 1	[98]
Destabilization/degradation	ZFN	Preclinical	[100,101]
	TALEN	Preclinical	[102,103]
	CRISPR/Cas9	Preclinical	[109-117]
SiRNA	PgRNA	ARC-520 in phase 2	[95]
Nucleocapsid assembly inhibitions	Capsid formation	BAY4109 in phase 1	[93,95]
Nucleocapsid assembly inhibitions	Capsid formation	NV1221 in phase 1	[93,95]
Reverse transcription inhibitions	Polymerase	TAF in phase 3	[93,94]
Reverse transcription inhibitions	Polymerase	Cmx157 in phase 1/2	[93,95]
HBsAg release inhibitions	HBsAg secretion	Preclinical	[109]
HBsAg release inhibitions	HBsAg secretion	Rep2139 in phase 1/2	[110]
Immune modulating	TLR-7 agonist	GS-9620 in phase 2	[67,68]
	HBV-specific	Preclinical	[84]
	cIAPS	Preclinical	[86]

cccDNA: Covalently-closed circular DNA; ZFN: Zinc finger nuclease; TALEN: Transcription activator-like effector nuclease; CRISPR: Clustered regularly interspaced short palindromic repeat; Cas: CRISPR associated system; pgRNA: Pregenomic RNAs; HBsAg: Hepatitis B virus surface antigen; TLR: Toll-like receptor; HBV: Hepatitis B virus; cIAPS: Cellular inhibitor of apoptosis proteins; DSS: Disubstituted sulfonamide; ASO: Antisense oligonucleotides; TAF: Tenofovir Alafenamide; NTCP: Na⁺/taurocholate cotransporting polypeptide.

Citation: Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873
URL: https://www.wjgnet.com/1948-5182/full/v8/i21/863.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i21.863